Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a ...

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

The biotech is entering a new era.

At 31, Molly Hones was preparing to die. She’d had a massive tumor removed from her liver the year prior, but was now ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike ...

Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA on Aug. 5, 2026 approved a new mRNA-based flu vaccine. (Melissa Phillip/AP) After months of regulatory questioning, the ...

A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said Wednesday, potentially opening up a new ...

The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.